AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03771638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet
Study NCT03771638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet
Study NCT03771638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT Diary mobile app
Description: DOT Diary mobile application for tracking medication adherence and sexual activities.
Study NCT01179217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
Study NCT01179217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
Study NCT01985711 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: web-based collaborative care
Description: Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months.
Study NCT01985711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: web-based collaborative care
Description: Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months.
Study NCT01985711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait-list
Description: Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
Study NCT01985711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wait-list
Description: Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
Study NCT01985711 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual diabetes outpatient care
Study NCT01152242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: insulin glargine
Description: Insulin glargine at 0.4 U/kg
Study NCT01985711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual diabetes outpatient care
Study NCT04489823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVP III
Description: Transcatheter closure of a paravalvular leak using AVP III
Study NCT02292602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Weight Control
Description: Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
Study NCT04464369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride
Description: itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
Study NCT04464369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills matching the look and weight of the itopride tablets
Study NCT02959853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Study NCT02788019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Study NCT02788019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Study NCT01647932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide according to clearance of creatinine; >50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
Study NCT03473730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03473730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03473730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03473730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy
Study NCT03473730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy
Study NCT00001360 — intervention group
Intervention type: DRUG
Intervention: 0-15 Water
Study NCT01647932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo according to clearance of creatinine; >50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
Study NCT02961634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nailner 2 in 1
Description: Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
Study NCT02961634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox 8%
Description: Ciclopirox 8% is a glaze used in the treatment of onychomycosis
Study NCT02961634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox 8%
Description: Ciclopirox 8% is a glaze used in the treatment of onychomycosis
Study NCT00993174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical strabismus surgery
Description: Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
Study NCT00993174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Tenon's strabismus surgery
Description: Surgery is carried out after sub-Tenon's injection of xylocaine
Study NCT03094546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine
Description: 12 months of polyamine supplementation (6 capsules/day)
Study NCT03094546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 months of placebo intake (6 capsules/day)
Study NCT01450657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics/Renadyl
Description: Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
Study NCT06426966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
Study NCT02959853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss
Study NCT02959853 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: weight loss
Study NCT03309319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rosiglitazone is added to the primary treatment
Study NCT01824810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular Stimulation
Description: Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle.
Study NCT02350790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic ablation
Description: Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
Study NCT02350790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic excision
Description: Robotic excision of endometriosis
Study NCT03553667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: Use radial arterial line to monitor mean arterial pressure
Study NCT03553667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
Study NCT03552263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsules (75mg), orally, twice daily.
Study NCT03552263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules (0mg), orally, twice daily.
Study NCT03552263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules (0mg), orally, twice daily.
Study NCT04255524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optic coherence tomography angiography (OCTA)
Description: Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
Study NCT02128178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 2 hours before arm
Description: Enoxaparin 40 mg 2 hours before surgery
Study NCT02128178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 12 hours before arm
Description: Enoxaparin 40 mg 12 hours before surgery
Study NCT02402127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study NCT02402127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study NCT06426966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre
Description: Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity.
Study NCT03975400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: search engine advertisement campaign
Description: This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
Study NCT03454256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Rehabilitation System
Study NCT02542943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 1
Description: (1.5% w/w KOX, pH 4.5)
Study NCT02542943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 2
Description: (1.5% w/w KOX, pH 7)
Study NCT02542943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse
Description: (0% w/w KOX, pH 4.5)
Study NCT02542943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard fluoride toothpaste
Description: 1000ppm fluoride as sodium monofluorophosphate
Study NCT02542943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard fluoride toothpaste
Description: 1000ppm fluoride as sodium monofluorophosphate
Study NCT03725020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
Study NCT03725020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride varnish
Description: The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
Study NCT02118922 — intervention group
Intervention type: PROCEDURE
Intervention: Brillouin imaging
Study NCT03570970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: Banapenem to be used anti-infection
Study NCT01202513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% topical ophthalmic solution
Study NCT03609359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
Study NCT03609359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study NCT00925366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging Procedure
Description: CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
Study NCT02823028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
Study NCT01824810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myoActivation
Description: In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
Study NCT01824810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural Prolotherapy
Description: Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
Study NCT01824810 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Needling Control
Description: The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
Study NCT02353819 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
Study NCT03551405 — intervention group
Intervention type: RADIATION
Intervention: CBCT scan
Description: CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
Study NCT03465397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biomarkers driven immunosuppressive therapy
Description: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
Study NCT01833728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nefopam-propacetamol combination
Description: Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
Study NCT01833728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propacetamol alone
Description: In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
Study NCT02548481 — intervention group
Intervention type: OTHER
Intervention: BESTA scale
Description: BESTA scale is administrated at T0, T1 and T2.
Study NCT02512523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Study NCT02512523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT02249949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efatutazone
Description: Given PO
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab were administered as a minimum 2-hour IV infusion.
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin were administered as a 2-hour IV infusion.
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin were administered as a 2-hour IV infusion.
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine
Description: Capecitabine were administered orally twice daily (bid).
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine were administered orally twice daily (bid).
Study NCT03653507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo were administered as a minimum 2-hour IV infusion.
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan